Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach.

Identifieur interne : 003677 ( PubMed/Curation ); précédent : 003676; suivant : 003678

Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach.

Auteurs : Richard C. Dodel [Allemagne] ; Helmut Höffken ; J Carsten Möller ; Bernhard Bornschein ; Thomas Klockgether ; Thomas Behr ; Wolfgang H. Oertel ; Uwe Siebert

Source :

RBID : pubmed:14531047

Descripteurs français

English descriptors

Abstract

As a diagnostic test for patients with suspected Parkinson's disease (PD), single photon emission computed tomography (SPECT) using [(123)I]FP-CIT tracer has better sensitivity but is more expensive than regular clinical examination (CE). Our objective was to evaluate the clinical and economic impacts of different diagnostic strategies involving [(123)I]FP-CIT SPECT. We developed a decision tree model to predict adequate treatment-month equivalents (ATME), costs, and incremental cost-effectiveness ratio (ICER) during a 12-month time horizon in patients with suspected PD referred to a specialized movement disorder outpatient clinic. In our cost- effectiveness analysis, we adopted the perspective of the German health care system and used data from a German prospective health care utilization study (n = 142) and published diagnostic studies. Compared strategies were CE only (EXAM+), SPECT only (SPECT+), SPECT following negative CE (SINGLE+), and SPECT following positive CE (DOUBLE+). Costs of SPECT amounted to euro;789 per investigation. Based on our model, expected costs (and ATME) were euro;946 (52.85 ATME) for EXAM+, euro;1352 (53.40 ATME) for DOUBLE+, euro;1731 (32.82 ATME) for SINGLE+, and euro;2003 (32.96 ATME) for SPECT+; performance of SPECT was induced in 0%, 54%, 56%, and 100% of the patients, respectively. DOUBLE+ was more effective and less expensive than SINGLE+ or SPECT+; thus these two do not offer reasonable choices. The ICER of DOUBLE+ compared to EXAM+ was euro;733 per ATME gained. In sensitivity analyses, the ICER of DOUBLE+ versus EXAM+ ranged from euro;63 to euro;2411 per ATME gained. Whether the diagnostic work-up of patients referred to a specialized movement disorder clinic with a high prevalence of PD should include [(123)I]FP-CIT SPECT depends on patient preferences and the decision maker's willingness to pay for adequate early treatment. SPECT should be used as a confirmatory test before treatment initiation and limited to patients with a positive test result in the clinical examination. These results should be adjusted to the specific setting and individual patient preferences.

DOI: 10.1002/mds.10580
PubMed: 14531047

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:14531047

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach.</title>
<author>
<name sortKey="Dodel, Richard C" sort="Dodel, Richard C" uniqKey="Dodel R" first="Richard C" last="Dodel">Richard C. Dodel</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Neurology, Friedrich-Wilhelms-University, Bonn, Germany. richard.dodel@ukb.uni-bonn.de</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Friedrich-Wilhelms-University, Bonn</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Hoffken, Helmut" sort="Hoffken, Helmut" uniqKey="Hoffken H" first="Helmut" last="Höffken">Helmut Höffken</name>
</author>
<author>
<name sortKey="Moller, J Carsten" sort="Moller, J Carsten" uniqKey="Moller J" first="J Carsten" last="Möller">J Carsten Möller</name>
</author>
<author>
<name sortKey="Bornschein, Bernhard" sort="Bornschein, Bernhard" uniqKey="Bornschein B" first="Bernhard" last="Bornschein">Bernhard Bornschein</name>
</author>
<author>
<name sortKey="Klockgether, Thomas" sort="Klockgether, Thomas" uniqKey="Klockgether T" first="Thomas" last="Klockgether">Thomas Klockgether</name>
</author>
<author>
<name sortKey="Behr, Thomas" sort="Behr, Thomas" uniqKey="Behr T" first="Thomas" last="Behr">Thomas Behr</name>
</author>
<author>
<name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H" last="Oertel">Wolfgang H. Oertel</name>
</author>
<author>
<name sortKey="Siebert, Uwe" sort="Siebert, Uwe" uniqKey="Siebert U" first="Uwe" last="Siebert">Uwe Siebert</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2003">2003</date>
<idno type="RBID">pubmed:14531047</idno>
<idno type="pmid">14531047</idno>
<idno type="doi">10.1002/mds.10580</idno>
<idno type="wicri:Area/PubMed/Corpus">003677</idno>
<idno type="wicri:Area/PubMed/Curation">003677</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach.</title>
<author>
<name sortKey="Dodel, Richard C" sort="Dodel, Richard C" uniqKey="Dodel R" first="Richard C" last="Dodel">Richard C. Dodel</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Neurology, Friedrich-Wilhelms-University, Bonn, Germany. richard.dodel@ukb.uni-bonn.de</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Friedrich-Wilhelms-University, Bonn</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Hoffken, Helmut" sort="Hoffken, Helmut" uniqKey="Hoffken H" first="Helmut" last="Höffken">Helmut Höffken</name>
</author>
<author>
<name sortKey="Moller, J Carsten" sort="Moller, J Carsten" uniqKey="Moller J" first="J Carsten" last="Möller">J Carsten Möller</name>
</author>
<author>
<name sortKey="Bornschein, Bernhard" sort="Bornschein, Bernhard" uniqKey="Bornschein B" first="Bernhard" last="Bornschein">Bernhard Bornschein</name>
</author>
<author>
<name sortKey="Klockgether, Thomas" sort="Klockgether, Thomas" uniqKey="Klockgether T" first="Thomas" last="Klockgether">Thomas Klockgether</name>
</author>
<author>
<name sortKey="Behr, Thomas" sort="Behr, Thomas" uniqKey="Behr T" first="Thomas" last="Behr">Thomas Behr</name>
</author>
<author>
<name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H" last="Oertel">Wolfgang H. Oertel</name>
</author>
<author>
<name sortKey="Siebert, Uwe" sort="Siebert, Uwe" uniqKey="Siebert U" first="Uwe" last="Siebert">Uwe Siebert</name>
</author>
</analytic>
<series>
<title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="2003" type="published">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Ambulatory Care Facilities (economics)</term>
<term>Brain (radionuclide imaging)</term>
<term>Cost-Benefit Analysis (statistics & numerical data)</term>
<term>Decision Trees</term>
<term>Dihydroxyphenylalanine (analogs & derivatives)</term>
<term>Dihydroxyphenylalanine (diagnostic use)</term>
<term>Dopamine Plasma Membrane Transport Proteins</term>
<term>Germany</term>
<term>Health Care Costs (statistics & numerical data)</term>
<term>Humans</term>
<term>Membrane Glycoproteins</term>
<term>Membrane Transport Proteins (analysis)</term>
<term>National Health Programs (economics)</term>
<term>Nerve Tissue Proteins</term>
<term>Neurologic Examination (economics)</term>
<term>Parkinson Disease (economics)</term>
<term>Parkinson Disease (radionuclide imaging)</term>
<term>Prospective Payment System (economics)</term>
<term>Referral and Consultation (economics)</term>
<term>Tomography, Emission-Computed, Single-Photon (economics)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en">
<term>Dihydroxyphenylalanine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en">
<term>Membrane Transport Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en">
<term>Dihydroxyphenylalanine</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en">
<term>Germany</term>
<term>Membrane Glycoproteins</term>
<term>Nerve Tissue Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en">
<term>Ambulatory Care Facilities</term>
<term>National Health Programs</term>
<term>Neurologic Examination</term>
<term>Parkinson Disease</term>
<term>Prospective Payment System</term>
<term>Referral and Consultation</term>
<term>Tomography, Emission-Computed, Single-Photon</term>
</keywords>
<keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en">
<term>Brain</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en">
<term>Cost-Benefit Analysis</term>
<term>Health Care Costs</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Decision Trees</term>
<term>Dopamine Plasma Membrane Transport Proteins</term>
<term>Humans</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr">
<term>Allemagne</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">As a diagnostic test for patients with suspected Parkinson's disease (PD), single photon emission computed tomography (SPECT) using [(123)I]FP-CIT tracer has better sensitivity but is more expensive than regular clinical examination (CE). Our objective was to evaluate the clinical and economic impacts of different diagnostic strategies involving [(123)I]FP-CIT SPECT. We developed a decision tree model to predict adequate treatment-month equivalents (ATME), costs, and incremental cost-effectiveness ratio (ICER) during a 12-month time horizon in patients with suspected PD referred to a specialized movement disorder outpatient clinic. In our cost- effectiveness analysis, we adopted the perspective of the German health care system and used data from a German prospective health care utilization study (n = 142) and published diagnostic studies. Compared strategies were CE only (EXAM+), SPECT only (SPECT+), SPECT following negative CE (SINGLE+), and SPECT following positive CE (DOUBLE+). Costs of SPECT amounted to euro;789 per investigation. Based on our model, expected costs (and ATME) were euro;946 (52.85 ATME) for EXAM+, euro;1352 (53.40 ATME) for DOUBLE+, euro;1731 (32.82 ATME) for SINGLE+, and euro;2003 (32.96 ATME) for SPECT+; performance of SPECT was induced in 0%, 54%, 56%, and 100% of the patients, respectively. DOUBLE+ was more effective and less expensive than SINGLE+ or SPECT+; thus these two do not offer reasonable choices. The ICER of DOUBLE+ compared to EXAM+ was euro;733 per ATME gained. In sensitivity analyses, the ICER of DOUBLE+ versus EXAM+ ranged from euro;63 to euro;2411 per ATME gained. Whether the diagnostic work-up of patients referred to a specialized movement disorder clinic with a high prevalence of PD should include [(123)I]FP-CIT SPECT depends on patient preferences and the decision maker's willingness to pay for adequate early treatment. SPECT should be used as a confirmatory test before treatment initiation and limited to patients with a positive test result in the clinical examination. These results should be adjusted to the specific setting and individual patient preferences.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">14531047</PMID>
<DateCreated>
<Year>2003</Year>
<Month>10</Month>
<Day>07</Day>
</DateCreated>
<DateCompleted>
<Year>2004</Year>
<Month>03</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised>
<Year>2012</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>18 Suppl 7</Volume>
<PubDate>
<Year>2003</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach.</ArticleTitle>
<Pagination>
<MedlinePgn>S52-62</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>As a diagnostic test for patients with suspected Parkinson's disease (PD), single photon emission computed tomography (SPECT) using [(123)I]FP-CIT tracer has better sensitivity but is more expensive than regular clinical examination (CE). Our objective was to evaluate the clinical and economic impacts of different diagnostic strategies involving [(123)I]FP-CIT SPECT. We developed a decision tree model to predict adequate treatment-month equivalents (ATME), costs, and incremental cost-effectiveness ratio (ICER) during a 12-month time horizon in patients with suspected PD referred to a specialized movement disorder outpatient clinic. In our cost- effectiveness analysis, we adopted the perspective of the German health care system and used data from a German prospective health care utilization study (n = 142) and published diagnostic studies. Compared strategies were CE only (EXAM+), SPECT only (SPECT+), SPECT following negative CE (SINGLE+), and SPECT following positive CE (DOUBLE+). Costs of SPECT amounted to euro;789 per investigation. Based on our model, expected costs (and ATME) were euro;946 (52.85 ATME) for EXAM+, euro;1352 (53.40 ATME) for DOUBLE+, euro;1731 (32.82 ATME) for SINGLE+, and euro;2003 (32.96 ATME) for SPECT+; performance of SPECT was induced in 0%, 54%, 56%, and 100% of the patients, respectively. DOUBLE+ was more effective and less expensive than SINGLE+ or SPECT+; thus these two do not offer reasonable choices. The ICER of DOUBLE+ compared to EXAM+ was euro;733 per ATME gained. In sensitivity analyses, the ICER of DOUBLE+ versus EXAM+ ranged from euro;63 to euro;2411 per ATME gained. Whether the diagnostic work-up of patients referred to a specialized movement disorder clinic with a high prevalence of PD should include [(123)I]FP-CIT SPECT depends on patient preferences and the decision maker's willingness to pay for adequate early treatment. SPECT should be used as a confirmatory test before treatment initiation and limited to patients with a positive test result in the clinical examination. These results should be adjusted to the specific setting and individual patient preferences.</AbstractText>
<CopyrightInformation>Copyright 2003 Movement Disorder Society</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Dodel</LastName>
<ForeName>Richard C</ForeName>
<Initials>RC</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Friedrich-Wilhelms-University, Bonn, Germany. richard.dodel@ukb.uni-bonn.de</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Höffken</LastName>
<ForeName>Helmut</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Möller</LastName>
<ForeName>J Carsten</ForeName>
<Initials>JC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bornschein</LastName>
<ForeName>Bernhard</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Klockgether</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Behr</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Oertel</LastName>
<ForeName>Wolfgang H</ForeName>
<Initials>WH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Siebert</LastName>
<ForeName>Uwe</ForeName>
<Initials>U</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050483">Dopamine Plasma Membrane Transport Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>2C598205QX</RegistryNumber>
<NameOfSubstance UI="C043437">fluorodopa F 18</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>63-84-3</RegistryNumber>
<NameOfSubstance UI="D004295">Dihydroxyphenylalanine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000554">Ambulatory Care Facilities</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003362">Cost-Benefit Analysis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000706">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D003663">Decision Trees</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004295">Dihydroxyphenylalanine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs & derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D050483">Dopamine Plasma Membrane Transport Proteins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D005858">Germany</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017048">Health Care Costs</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000706">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D008562">Membrane Glycoproteins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D026901">Membrane Transport Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009313">National Health Programs</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009419">Nerve Tissue Proteins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009460">Neurologic Examination</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011445">Prospective Payment System</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012017">Referral and Consultation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D015899">Tomography, Emission-Computed, Single-Photon</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2003</Year>
<Month>10</Month>
<Day>8</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2004</Year>
<Month>3</Month>
<Day>30</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2003</Year>
<Month>10</Month>
<Day>8</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">14531047</ArticleId>
<ArticleId IdType="doi">10.1002/mds.10580</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003677 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003677 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:14531047
   |texte=   Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:14531047" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3 

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024